Skip to main content
Caplight Logo









Neoclease

Neoclease

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://neoclease.ai/

Last Round

Accelerator

Sep 1, 2026

Total Funding Raised

$283,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neoclease is a biotechnology company that develops custom, gene-specific nucleases using generative AI and synthetic biology for precision gene editing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

gene editinggenerative AIprotein engineeringtechbionuclease designdrug discoveryprecision medicinetherapeutic gene editorsgenomic medicineAI drug discoveryin silico protein designCRISPR alternativesbiotech platformprotein designAI protein folding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neoclease Comparables

Compare Neoclease with similar companies based on industry and business-model similarity.

Neoclease comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Profluent Bio
73%
Arbor Biotechnologies
73%
Mammoth Biosciences
71%

Neoclease Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorSep 1, 2026
AcceleratorJul 23, 2026
AcceleratorJul 1, 2025
GrantJun 18, 2025
AcceleratorJun 13, 2025
Grant
May 21, 2025

Key People

Founding team and executive leadership

Chelsea Trengrove, PhD

CEO and Cofounder

Founding Team

Neoclease Investors

Notable investors and investment history

Neoclease investors
InvestorRounds
The EngineAccelerator
Creative Destruction LabAccelerator
C10 LabsAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2026

    Received funding from MassBio.

  • Jul 24, 2026

    Monthly visitors grew 675% MoM, reaching 1.1K.

Neoclease Filings

Explore SEC and related filing metadata, where available.

Neoclease filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neoclease's valuation, stock price, and market status.

Is Neoclease a public or private company?

Neoclease is a private company.

What is the current stock price of Neoclease?

Neoclease is a private company with no public stock price. Caplight tracks Neoclease's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Neoclease worth (valuation)?

Valuation information for Neoclease is not publicly available.

Can I buy Neoclease stock?

Neoclease shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neoclease's last funding round?

Neoclease's most recent funding round was Accelerator on September 1, 2026.

Who are the main investors in Neoclease?

Key investors in Neoclease include The Engine, Creative Destruction Lab, C10 Labs.

Will Neoclease IPO soon?

No public IPO plans have been announced for Neoclease.

How can I track Neoclease secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neoclease's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range4
Year Founded2023
Last FundingSep 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?